Pfizer named Elizabeth Barrett regional president, US for its Oncology Business Unit, a new position, with responsibility for Pfizer’s US oncology sales, field operations and marketing.
Barrett joins the company from Cephalon, where she was VP and general manager of the company’s Oncology Business Unit. There, she launched the company into oncology in an integrated business unit, presiding over the marketing, sales and medical affairs organizations and developing the firm’s strategy in the category.
Before joining Cephalon, she served as worldwide VP of sales and marketing for Veridex and VP of the critical care and surgery franchise at Ortho Biotech.
Barrett will report to Garry Nicholson, president and general manager, Oncology Business Unit.
Nicholson hailed her expertise in oncology and said: “As the Oncology Business Unit continues to explore and build upon new areas and tumor types, it is important that we have the right leaders in place to ensure that we can deliver superior total value not only internally within the company, but to the physicians and patients that we serve.”
Pfizer’s oncology portfolio includes Sutent, for renal cell carcinoma and GIST, and Aromasin for breast cancer.
